Literature DB >> 16458421

Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis.

Moritz N Wente1, Michael P Keane, Marie D Burdick, Helmut Friess, Markus W Büchler, Güralp O Ceyhan, Howard A Reber, Robert M Strieter, Oscar J Hines.   

Abstract

A central feature of all solid tumor growth is the presence of neovascularization. The CXC chemokines GRO-gamma/CXCL3, ENA-78/CXCL5, and IL-8/CXCL8 have profound angiogenic potential mediated through the CXCR2 receptor. The aim of the present study was to evaluate the expression of the angiogenic chemokines in three human pancreatic cancer cell lines and to determine the role of these proteins in pancreatic cancer angiogenesis. Secreted CXC protein levels in the supernatant of the cell lines were analyzed by ELISA. A rat corneal micropocket model was used to determine the angiogenic potential of these secreted CXC chemokines in vivo. ELISA confirmed expression of all three tested CXC chemokines in the supernatant of two cell lines. In the corneal micropocket assay, neovascularization was induced using pelleted supernatant of all three-cell lines. Using an anti-CXCR2 antibody, neovascularization was significantly inhibited in the high expressing BxPC-3 cell line samples. In addition, the expression of ENA-78/CXCL5 and IL-8/CXCL8 has been evaluated in human pancreatic cancer tissue samples by using immunohistochemistry in order to further investigate the potential role of CXC chemokines in pancreatic cancer angiogenesis and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458421     DOI: 10.1016/j.canlet.2005.10.041

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  56 in total

1.  Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.

Authors:  Shi-Liang Gui; Li-Chen Teng; Shu-Qiu Wang; Shuang Liu; Ying-Li Lin; Xiao-Lian Zhao; Lei Liu; Hong-Yu Sui; Yang Yang; Li-Chun Liang; Mo-Lin Wang; Xin-Yi Li; Yu Cao; Feng-Ying Li; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2016-02-02       Impact factor: 2.370

Review 2.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

Review 3.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 4.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

Review 5.  Neutrophils: key mediators of tumour angiogenesis.

Authors:  Simon Tazzyman; Claire E Lewis; Craig Murdoch
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

6.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 7.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

Review 8.  CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.

Authors:  Timothy R Donahue; O Joe Hines
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

Review 9.  Angiogenesis and its targeting in rheumatoid arthritis.

Authors:  Zoltán Szekanecz; Alisa E Koch
Journal:  Vascul Pharmacol       Date:  2009-02-13       Impact factor: 5.773

10.  Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.

Authors:  Kaouther Snoussi; Wijden Mahfoudh; Noureddine Bouaouina; Meriem Fekih; Hedi Khairi; Ahmed N Helal; Lotfi Chouchane
Journal:  BMC Cancer       Date:  2010-06-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.